In this context, the changes in LIFR expression could be related to susceptibility to NAFLD and insulin resistance in patients with LADA, and the LIFR/JAK/STAT3 inflammatory pathway enhances adipocyte lipolysis [21]. Here, STAT3 is linked to metabolic dysfunction-associated steatotic liver disease.